EHA Library; Kater A. Jun 12 2021; 330172;
Data presented at #EHA2021 from phase III glow study of Ibr+Ven vs Clorambucil+Obinutuzimab in front line CLL. Included older patients or younger patients with comorbidities and excluded 17p. At medan f/u of 27 months mPFS was not reached in the VEN+Ibr arm and was 21 months for Obi+Cl. Higher rate of MRD negativity in the IBr+Ven arm as well. 84% of patients at high risk for TLS became low medium risk with three month Ibrutinib lead in. 6.6% of patients in the IBr+Ven arm died due to toxicity.